Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis

Acta Neurologica Scandinavica

Volumn 109, Issue 3, 2004, Pages 222-227

  Szolnoki, Z ^a,c   Somogyvari F ^a   Kondacs, A ^a   Szabo M ^a   Fodor, L ^a   Bene, J ^b   Melegh, B ^b  

^a Pandy Kalman Bekes County Hospital   (Hungary)

^b UNIVERSITY OF PÉCS   (Hungary)

^c NONE   (Hungary)

Author keywords

Genetic interaction; Genetics; Leukoaraiosis; Risk factors

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CAUCASIAN; CONTROLLED STUDY; DEMYELINATING DISEASE; FEMALE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HUMAN; LEUKOARAIOSIS; MAJOR CLINICAL STUDY; MALE; MUTATION; NEUROIMAGING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; DEMENTIA, VASCULAR; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; MAGNETIC RESONANCE IMAGING; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; PEPTIDES; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; PROTEIN INTERACTION MAPPING; REFERENCE VALUES; RISK;

EID: 1442325356     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-0404.2003.00218.x     Document Type: Article

References (36)

1. VAN GIJN J. Leukoaraiosis and vascular dementia. Neurology 1998;51(Suppl. 3):3-8.
2. STEINGART A, HACHINSKI VC, LAU C et al. Cognitive and neurologic findings in demented patients with diffuse white matter lucencies on computed tomographic scan (LeukoAraiosis). Arch Neurol 1987;44:36-9.
3. HACHINSKI VC, POTTER P, MERSKEY H. Leuko-Araiosis. Arch Neurol 1987;44:21-3.
4. JUNQUE C, PUJOL J, VENDRELL P et al. Leuko-araiosis on magnetic resonance imaging and speed of mental processing. Arch Neurol 1990;47:151-6.
5. LIU CK, MILLER BL, CUMMINGS JL et al. A quantitative MRI study of vascular dementia. Neurology 1992;42:138-43.
6. YLIKOSKI R, YLIKOSKI A, ERKINJUNTTI T, SULKAVA R, RAININKO R, TILVIS R. White matter changes in healthy elderly persons correlate with attention and speed of mental processing. Arch Neurol 1993;50:818-24.
7. HACHINSKI VC, POTTER P, MERSKEY H. Leuko-araiosis: an ancient term for a new problem. Can J Neurol Sci 1986;13:533-34.
8. PANTONI L, GARCIA JH. Pathogenesis of leukoaraiosis, a review. Stroke 1997;28:652-59.
9. INZITARI D, DIAZ F, FOX A et al. Vascular risk factors and leuko-araiosis. Arch Neurol 1987;44:42-7.
10. WISZNIEWSKA M, DEVUYST G, BOGOUSSLAVSKY J, GHIKA J, VAN MELLE G. What is the significance of leukoaraiosis in patients with acute ischemic stroke? Arch Neurol 2000;57:967-73.
11. SPOLVERI S, BARUFFI MC, CAPPELLETTI C et al. Vascular risk factors linked to multiple lacunar infarcts. Cerebrovasc Dis 1998;8:152-7.
12. LEYS D, ENGLUND E, DEL SER T et al. . White matter changes in stroke patients. Relationship with stroke subtype and outcome (Review). Eur Neurol 1999;42:67-75.
13. PANTONI L. Pathophysiology of age-related cerebral white matter change. Cerebrovasc Dis 2002;2:7-10.
14. AMAR K, MACGOWAN S, WILCOCK G, LEWIS T, SCOTT M. Are genetic factors important in the aetiology of leukoaraiosis? Results from a memory clinic population. Int J Geriat Psychiatry 1998;13:585-90.
15. SCHMIDT H, FAZEKAS F, KOSTNER GM, VAN DUIJN CMC, SCHMIDT R. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian stroke prevention study. Stroke 2001;32:405-412.
16. SCHMIDT R, SCHMIDT H, FAZEKAS F et al. Apolipoprotein E polymorphism and silent microangiopathy-related cerebral damage. Results of the Austrian Stroke Prevention Study. Stroke 1997;28:951-6.
17. SAWADA H, UDAKA F, IZUMI Y et al. Cerebral white matter lesions are not associated with ApoE genotype but with age and female sex in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;68:653-6.
18. SCHMIDT R, SCHMIDT H, FAZEKAS F et al. MRI cerebral white matter lesions and paraoxonase PON1 polymophism : three-year follow-up of the Austrian stroke prevention study. Arterioscler Thromb Vasc Biol 2000;20:1811-6.
19. LIU Y, LAAKSO MP, KARONEN JO et al. Apolipoprotein E polymorphism and acute ischaemic stroke: a diffusion- and perfusion-weighted magnetic resonance imaging study. J Cereb Blood Flow Metab 2002;22:1336-42.
20. AALTO-SETALA K, PALOMAKI H, MIETTINEN H et al. Genetic risk factors and ischaemic cerebrovascular disease: role of common variation of the genes encoding apolipoprotein and angiotensin-converting enzyme. Ann Med 1998;30:224-33.
21. SZOLNOKI Z, SOMOGYVÁRI F, KONDACS A, SZABÓ M, FODOR L. Evaluation of the interactions of common genetic mutations in stroke subtypes. J Neurol 2002;249:1391-7.
22. BATALLA A, ALVAREZ R, REGUERO JR et al. Synergistic effect between apolipoprotein E and angiotensin gene polymorphism in the risk for early myocardial infarction. Clin Chem 2000;46:1910-5.
23. SZOLNOKI Z, SOMOGYVÁRI F, KONDACS A, SZABÓ M, FODOR L. Evaluation of the roles of common genetic mutations in leukoaraiosis. Acta Neurol Scand 2001;104:281-7.
24. FAZEKAS F, CHAWLUK JB, ALAVI A, HURTIG HI, ZIMMERMAN RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am Roentgenol 1987;149:351-6.
25. FAZEKAS F, KLEINERT R, OFFENBACHER H et al. Pathologic correlate of incidental MRI white matter signal hyperintensities. Neurology 1993;43:1683-9.
26. HASSAN A, MARKUS HS. Genetics and ischaemic stroke. Brain 2000;123:1784-812.
27. CROOK R, HARDY J, DUFF K, Single-day apolipoprotein E genotyping of. J Neurosci Methods 1994;53:125-7.
28. CLARK ZE, BOWEN DJ, WHATLEY SD, BELLAMY MF, COLLINS PW, MCDOWELL IF. Genotyping method for methylene-tetrahydrofolate reductase (C677T) thermolabile variant using heteroduplex technology. Clin Chem 1998;44:2360-2.
29. SOMOGYVÁRI F, SZOLNOKI Z, MÁRKI-ZAY J, FODOR L. REAL-TIME PCR Assay with fluorescent hybridization probes for exact and rapid genotyping of the angiotensin-converting enzyme gene insertion/deletion polymorphism. Clin Chem 2001;47:1728-9.
30. GROUP WS. Report on diabetes mellitus. WHO Tech Rep Ser 1985;727.
31. EVERS S, KOCH HG, GROTEMEYER KH, LANGE B, DEUFEL T, RINGELSTEIN EB. Features, symptoms, and neurophysiological findings in stroke associated with hyperhomocysteinemia. Arch Neurol 1997;54:1276-82.
32. MARKUS HS, BARLEY J, LUNT R et al. Angiotensin-converting enzyme gene deletion polymorphism. A new risk factor for lacunar stroke but not carotid atheroma. Stroke 1995;26:1329-33.
33. MALIK FS, LAVIE CJ, MEHRA MR, MILANI RV, RE RN. Valvular and congenital heart disease. Renin-angiotensin system: genes to bedside. Am Heart J 1997;134:514-27.
34. STRITTMATTER WJ, SAUNDERS AM, GOEDERT M et al. Isoform-specific interactions of APOEE with microtubule associated protein tau: implication for Alzheimer disease. Proc Natl Acad Sci USA 1994;91:11183-6.
35. STRITTMATTER WJ, WEISGRABER KH, GOEDERT M et al. Hypothesis: microtubule instability and paired helical filament formation in the Alzheimer's disease brain are related to apolipoprotein E genotype. Exp Neurol 1994;125:163.
36. BURKHART KK, BEARD DC, LEHMAN RA, BILLINGSLEY ML. Alteration in Tau phosphorylation in rat and human neocortical brain slices following hypoxia and glucose deprivation. Exp Neurol 1998;154:464-7.